Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
Join the Thermo Fisher Scientific team at CE PHARM 2018. At this event we will be showcasing the newly-released GlycanAssure HyPerformance kit. This new platform provides consistent and accurate data through complete deglycosylation and preservation of sialic acid.
At the booth you will have the opportunity to learn more about this eye-opening glycan analysis technology. Several staff members belong to our Research & Development group and are directly responsible for developing the GlycanAssure platform. This is the perfect opportunity to get the most accurate guidance.
The GlycanAssure HyPerformance APTS kit provides a rapid 3-step magnetic bead-based workflow for preparation of N-linked glycans in <1.5 hours with complete deglycosylation and preservation of sialic acid. Orthogonal analysis on CE or LC yields accurate and consistent data.
We will also be showcasing the Applied Biosystems 3500 Genetic Analyzer for Protein Quality Analysis. This capillary electrophoresis instrument enables parallel analysis of up to 24 samples without compromising on the run time per sample, thereby enabling high throughput analysis with high quality data. Additionally, we will feature a demo of our GlycanAssure software, an easy-to-use software solution for fast glycan analysis with a module to help meet 21CFR Part11 compliance. Together, the 3500 instrument and the GlycanAssure software are key elements in the GlycanAssure Hyperformance workflow.
Learn about our fully automated solution for glycan sample prep. The GlycanAssure AutoXpress APTS kit combines the GlycanAssure HyPerformance APTS reagents with the Applied Biosystems AutoMate Express instrument. 13 samples are processed in under 2 hours with only 5 minutes of hands-on time.
Attend our customer talk: Host Glycomic Determinants of Interferon-α-Mediated Reduction of HIV Persistence in vivo | |
---|---|
Time | Tuesday; September 11, 3:45pm at Plaza Room B |
Speaker | Mohamed Abdel-Mohsen, Assistant Professor, Vaccine & Immunotherapy Center, The Wistar Institute |
Abstract | Interferon-α (IFNα) therapy was associated with significant suppression of HIV viremia and reduction in levels of HIV DNA during suppressive antiretroviral therapy (ART). Cytokines modulate host glycosylation machinery, and glycosylation plays a critical role in mediating several antibody immunological functions. We assessed the impact of pegylated IFNα2a (Peg-IFNα2a) immunotherapy on isolated IgG glycomes of 18 HIV-mono-infected individuals on suppressive ART, using the GlycanAssure HyPerformance assay with capillary electrophoresis analysis. Peg-IFNα2a treatment was associated with
|
![]() | Dr. Abdel-Mohsen’s research focuses on investigating the role of host glycosylation machinery in viral persistence and immunopathogenesis. He joined The Wistar Institute as Assistant Professor in 2017 after completing his Ph.D. and postdoctoral training at the University of California, San Francisco (UCSF) and the Blood Systems Research Institute (BSRI), where he was subsequently appointed as a research scientist. Previously, he was a virologist for the World Health Organization Regional Reference Laboratory for poliovirus in his home country of Egypt. He received the UCSF-Gladstone CFAR Early-Career Award of Excellence in Basic Science in 2015. |
Fully automated GlycanAssure AutoXpress N-Glycan sample preparation for N-glycan analysis on UPLC and CE
Presenter: Nan Liu
High throughput and high resolution glycan and data analysis by capillary electrophoresis 3500xL Instrument
Presenter: Jen-Kuei Lin
Analysis of Highly Sialylated Samples on the GlycanAssure™ System
Presenter: Shaheer Khan
For Research Use Only. Not for use in diagnostic procedures.